Patents by Inventor Kyri Dunussi

Kyri Dunussi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for modulating interleukin-21 receptor activity
    Patent number: 7198789
    Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: April 3, 2007
    Assignee: Genetics Institute, LLC
    Inventors: Laura Carter, Beatriz Carreno, Leslie D. Lowe, Matthew J. Whitters, Kyri Dunussi, Mary Collins, Margery Ma, Deborah A. Young, JoAnn S. Witek, Glenn Larsen, Marion T. Kasaian, Debra D. Donaldson, Michelle Unger
  • Methods and compositions for modulating interleukin-21 receptor activity
    Publication number: 20030108549
    Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.
    Type: Application
    Filed: October 4, 2002
    Publication date: June 12, 2003
    Applicant: Wyeth
    Inventors: Laura Carter, Beatriz Carreno, Leslie D. Lowe, Matthew J. Whitters, Kyri Dunussi, Mary Collins, Margery Ma, Deborah A. Young, JoAnn S. Witek, Glenn Larsen, Marion T. Kasaian, Debra D. Donaldson, Michelle Unger